Capital Asset Advisory Services’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-3,941
Closed -$216K 292
2025
Q3
$216K Buy
3,941
+182
+5% +$9.09K 0.01% 262
2025
Q2
$205K Buy
+3,759
New +$191K 0.01% 262
2025
Q1
Sell
-3,676
Closed -$210K 289
2024
Q4
$210K Buy
3,676
+110
+3% +$6.84K 0.01% 301
2024
Q3
$245K Buy
+3,566
New +$201K 0.01% 283
2024
Q2
Sell
-3,463
Closed -$243K 318
2024
Q1
$243K Hold
3,463
0.01% 279
2023
Q4
$256K Hold
3,463
0.02% 257
2023
Q3
$232K Buy
3,463
+234
+7% +$19.9K 0.02% 282
2023
Q2
$313K Hold
3,229
0.02% 251
2023
Q1
$219K Buy
+3,229
New +$208K 0.02% 320
2021
Q1
Sell
-17
Closed -$2K 926
2020
Q4
$2K Buy
+17
New +$2.06K ﹤0.01% 1435

Other funds holding EXAS

Capital Asset Advisory Services's EXAS Position: Q4 2025 in Review

Capital Asset Advisory Services sold out of Exact Sciences (EXAS) in Q4 2025, closing a stake of 3,941 shares — an estimated $216K sold.

Capital Asset Advisory Services first reported a position in EXAS in Q4 2020 and held it in 10 quarters. The position peaked at $313K in Q2 2023. 711 funds tracked by Wall St. Rank hold EXAS as of Q4 2025.

  • Capital Asset Advisory Services reported no remaining Exact Sciences position as of Q4 2025 after selling out during the quarter.
  • Capital Asset Advisory Services sold 3,941 Exact Sciences shares in Q4 2025, an estimated $216K.
  • Capital Asset Advisory Services first reported a position in Exact Sciences in Q4 2020 and held it in 10 quarters.
  • Capital Asset Advisory Services's Exact Sciences position peaked at $313K in Q2 2023.
  • 711 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2025.

Based on Capital Asset Advisory Services's 13F filing for Q4 2025, filed 9 Jan 2026.